Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71209-019

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71209-019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil-spl-cont-label-10mg-1000tab (Donepezil Spl Cont Label 10mg 1000tab)

FDA Label Image

Donepezil-spl-cont-label-10mg-30tab (Donepezil Spl Cont Label 10mg 30tab)

This is a description of a medication that contains Dorl hydrochloride and Donepezil Hydrochloride in tablet form. The tablets are coated and must be stored in a controlled room temperature between 59°F to 86°F (15°C to 30°C). They should be dispensed in tight containers and the packaging includes dosage and usage instructions. The manufacturer is CADILA PHARMACEUTICALS LTD in India.*

FDA Label Image

Donepezil-spl-cont-label-10mg-90tab (Donepezil Spl Cont Label 10mg 90tab)

Each film-coated tablet contains 10 mg of Donepezil Hydrochloride USP. This medication is prescribed to treat dementia related to Alzheimer's disease. The tablets should be stored at temperatures between 15°C and 30°C. The medication should be dispensed in tight containers that conform to the USP standards. It is manufactured by Cadila Pharmaceuticals Ltd. in India.*

FDA Label Image

Donepezil-spl-cont-label-5mg-1000tab (Donepezil Spl Cont Label 5mg 1000tab)

This is a medication description for Donepezil Hydrochloride Tablets USP, manufactured by Cadila Pharmaceuticals Ltd. The tablets are coated and each tablet contains 5 mg of Donepezil Hydrochloride USP. The dosage and usage information must be obtained from the prescribing information. The tablets should be stored in tight containers at room temperature between 59°F to 86°F. The product is only available on prescription and comes in a pack of 1000 tablets. The National Drug Code (NDC) for this product is 71209-019-11.*

FDA Label Image

Donepezil-spl-cont-label-5mg-30tab (Donepezil Spl Cont Label 5mg 30tab)

Each tablet of Donepezil hydrochloride USP 5mg is film-coated and has the NDC number 71209-019-01. The recommended dosage and instructions for use can be found in the accompanying prescribing information. The tablets should be stored at a controlled room temperature between 59° to 86°F (15° to 30°C). They should only be dispensed in USP containers. The manufacturer is CADILA PHARMACEUTICALS LTD. located in Bhid 1389, Dhlka, Dist, Ahmedabid, Gujarat, DA.*

FDA Label Image

Donepezil-spl-cont-label-5mg-90tab (Donepezil Spl Cont Label 5mg 90tab)

Each film-coated tablet of Donepezi Hydrochloride USP 5mg contains NG71203-019-04. It is a prescription medication used for treatment and should be used as per the prescribing information. Store in a cool and dry place between 15 to 30 degree Celsius, in a tight container, and out of reach of children. Manufactured by Cadila Pharmaceuticals Ltd. in India.*

FDA Label Image

Fig1 (Donepezil Spl Fig 01)

FDA Label Image

Fig2 (Donepezil Spl Fig 02)

FDA Label Image

Fig3 (Donepezil Spl Fig 03)

This is a table that displays information about Donepezil Hydrochloride Tablets dosage of 10 mg/day and 5 mg/day. There is also an option for Placebo. The table also includes a rating scale from Markedly Improved to Worse using CIBIC plus Rating.*

FDA Label Image

Fig4 (Donepezil Spl Fig 04)

FDA Label Image

Fig5 (Donepezil Spl Fig 05)

FDA Label Image

Fig6 (Donepezil Spl Fig 06)

This appears to be a chart or graph showing the percentage of patients who experienced different levels of improvement after taking either Donepezil Hydrochloride tablets at 10mg/day or 5mg/day. The chart shows different levels of improvement, ranging from markedly improved to markedly worse, as well as the percentage of patients who experienced each level of improvement. There is also a CIBIC-plus rating included.*

FDA Label Image

Fig7 (Donepezil Spl Fig 07)

FDA Label Image

Fig8 (Donepezil Spl Fig 08)

This is a table representing the SIB (Severe Impairment Battery) change from baseline for three different treatments: Donepezil Hydrochloride, Placebo, and Tablets 10 mg/day. The table shows numerical values for each treatment option, but there is no additional information available to provide context or further explanation.*

FDA Label Image

Fig9 (Donepezil Spl Fig 09)

FDA Label Image

Fig10 (Donepezil Spl Fig 10)

FDA Label Image

Fig11 (Donepezil Spl Fig 11)

FDA Label Image

Fig12 (Donepezil Spl Fig 12)

FDA Label Image

Fig13 (Donepezil Spl Fig 13)

This is a data table showing the percentage of patients who experienced improvement or worsened based on their CIBIC-plus rating when taking Donepezil Hydrochloride tablets in varying dosages. Information on the dosages administered is also provided.*

FDA Label Image

Str (Donepezil Spl Struc)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.